About Compendia Bio
Compendia Bio is a Healthcare company based in Ann Arbor (United States) founded in 2006, and was acquired by Life Technologies in October 2012. Cancer genomics data is collected and analyzed for drug development. It operates in the Healthcare and Technology sectors. The company was acqui-hired. Its focus areas include HealthTech, Life Sciences Tech, Research & Development and Drug Discovery. Its competitors include Human Longevity, DNAnexus and Seven Bridges Genomics; 3 of its 3 listed competitors have raised funding.
Company details
Compendia Bioscience specializes in collecting, analyzing, and integrating cancer genomics data for drug development, diagnostics and personalized medicine. Data collection process includes direct correspondence with study authors to gather all available sample facts, often beyond those presented in the original publication. Its main products are Oncomine, aggregates and analyze the oncology data and provide practical, actionable views on the data and results. Oncopredictor, a biomarker discovery platform, performs comprehensive analyses to identify genomic biomarkers of in vitro drug response and importantly, predicts patient populations most likely to benefit from the drug, oncology companion diagnostics platform, Oncoscore, leverages the molecular diversity of cancer to provide deep molecular sub-typing of cancer patients. On October 8, 2012 the company was acquired by Life Technologies, which is a part of Thermo Fisher Scientific.
- Headquarters Ann Arbor, United States
- Stage Acquired
- SectorsHealthcareTechnology
- Website compendiabio.com
- Social LinkedIn X
- Acquired by Life Technologies (Oct 2012)
- Latest Funding Round$1.33M (USD), Grant
Aug 2010
- InvestorsHHS
& 1 more
- Acquired byLife Technologies
(Oct 2012)
Funding Insights of Compendia Bio
- Total Rounds 6
- Last Round Grant — $1.33M
- First Round $1.4M
(Sep 2007)
- Investors Count 1
All 6 funding rounds of Compendia Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
2 investors in total: 2 institutional.
Investors in Compendia Bio
Compendia Bio has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include HHS and Life Technologies.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Tools and technologies for biotech and biopharma research were supplied. | 1983 | lifetechnologies.com | Carlsbad, United States |
Investor details for Compendia Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Compendia Bio
4 dated milestones of Compendia Bio across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Compendia Bio is founded.
- Funding First funding round of $1.4M.
- Funding Latest funding round, Grant, of $1.3M.
- Exit Acquired by Life Technologies.
Competitors of Compendia Bio
Compendia Bio has 3 listed competitors in our database, 3 of them funded. They include Human Longevity, DNAnexus and Seven Bridges Genomics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| humanlongevity.com | 2013 | San Diego, United States | $376.72M | 83 | Genomics data and cell therapy-based diagnostic and therapeutic solutions | |
| dnanexus.com | 2009 | Mountain View, United States | $472.55M | 143 | Cloud-based genome informatics and data management are provided. | |
| sevenbridges.com | 2009 | Cambridge, United States | $113M | 112 | Cloud-based platform to analyze, store, and act on genomic data. |
Detailed competitors of Compendia Bio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Compendia Bio (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Compendia Bio
Compendia Bio was founded in 2006 and raised its 1st funding round 1 year after it was founded.
Compendia Bio is headquartered in Ann Arbor, United States. It is registered at Ann Arbor, Michigan, United States.
Compendia Bioscience specializes in collecting, analyzing, and integrating cancer genomics data for drug development, diagnostics and personalized medicine. Data collection process includes direct correspondence with study authors to gather all available sample facts, often beyond those presented in the original publication. Its main products are Oncomine, aggregates and analyze the oncology data and provide practical, actionable views on the data and results. Oncopredictor, a biomarker discovery platform, performs comprehensive analyses to identify genomic biomarkers of in vitro drug response and importantly, predicts patient populations most likely to benefit from the drug, oncology companion diagnostics platform, Oncoscore, leverages the molecular diversity of cancer to provide deep molecular sub-typing of cancer patients. On October 8, 2012 the company was acquired by Life Technologies, which is a part of Thermo Fisher Scientific.
Compendia Bio's top competitors include DNAnexus, Human Longevity and Seven Bridges Genomics.
Compendia Bio has 2 investors. Key investors include HHS, and Life Technologies.
Yes. Compendia Bio was acquired by Life Technologies in October 2012.